Get the Stockscreener App
47.89
0.50%
-0.24
Pre-market:
48.71
0.82
+1.71%
Rigel Pharmaceuticals stock is traded at $47.89, with a volume of 143.80K.
It is down -0.50% in the last 24 hours and up +6.16% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
See More
Previous Close:
$48.13
Open:
$47.87
24h Volume:
143.80K
Relative Volume:
0.47
Market Cap:
$894.58M
Revenue:
$299.77M
Net Income/Loss:
$364.23M
P/E Ratio:
2.5581
EPS:
18.7211
Net Cash Flow:
$79.27M
1W Performance:
+4.45%
1M Performance:
+6.16%
6M Performance:
+83.28%
1Y Performance:
+58.16%
1-Day Range:
$47.00
$48.14
1-Week Range:
$45.24
$49.02
52-Week Range:
$24.95
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
47.89 | 894.58M | 299.77M | 364.23M | 79.27M | 18.72 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Rigel Pharmaceuticals, Inc. (RIGL) Options ChainYahoo Finance - Yahoo! Finance Canada
Rigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment ConferenceSlideshow (NASDAQ:RIGL) 2026-09-15 - Seeking Alpha
Rigel Pharmaceuticals at H.C. Wainwright conference: growth plan broadens - Investing.com
Rigel Pharmaceuticals at H.C. Wainwright conference: growth plan broadens By Investing.com - Investing.com Australia
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare ConferenceSlideshow (NASDAQ:RIGL) 2026-09-15 - Seeking Alpha
Precision Trading with Rigel Pharmaceuticals Inc. (RIGL) Risk Zones - news.stocktradersdaily.com
RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside? - Stocktwits
Rigel Pharmaceuticals at Cantor conference: veppanu launch leads growth push - Investing.com Nigeria
Rigel Pharmaceuticals at Cantor conference: veppanu launch leads growth push By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals (RIGL) Institutional Ownership 2026 $RIGL - MarketBeat
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $85 - Moomoo
Trading the Move, Not the Narrative: (RIGL) Edition - Stock Traders Daily
EVP & Chief Financial Officer At Rigel Pharmaceuticals Exercises Options Worth $123K - Benzinga
Rigel (NASDAQ: RIGL) CCO now holds 61,622 shares - Stock Titan
Rigel Pharmaceuticals (RIGL) CEO returns 2,424 shares to issuer - Stock Titan
Rigel Pharmaceuticals (NASDAQ: RIGL) insider now holds 50,559 shares - Stock Titan
Rigel Pharmaceuticals CFO to present at three m... - Pluang
Rigel to Participate in Upcoming September Investor Conferences - PR Newswire
Rigel Pharmaceuticals (RIGL) CFO exercises options and uses shares to cover taxes - Stock Titan
Rigel Pharmaceuticals Inc. (RIGL) Peer Comparison – Compare with Others - Value Research
Rigel (RIGL) Results Breakdown: EPS Exceeds Its Estimate for the Current Session; Market Reaction: Shares Finish 3.64% Down in Latest TradingSurprise Factor Analysis - Vinanet
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research - MarketBeat
HC Wainwright Analysts Increase Earnings Estimates for RIGL - MarketBeat
Rigel Pharmaceuticals Inc (RIGL) (Q2 2026) Earnings Call Highlig - GuruFocus
Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $49 - Moomoo
RIGL Maintains Neutral Rating -- Price Target Raised to $49.00 b - GuruFocus
Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope - Yahoo Finance
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
(RIGL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85 - GuruFocus
Armistice Capital (RIGL) reports 1.67M Rigel Pharmaceuticals shares in 13G/A - Stock Titan
Rigel announces availability of Veppanu in the USA - The Pharma Letter
Rigel Says Breast Cancer Drug Veppanu Now Available in US, Puerto Rico - marketscreener.com
Rigel Pharmaceuticals (RIGL): Soleus Capital group discloses 9.9% ownership stake - Stock Titan
Rigel's VEPPANU Is Now Available for Certain Advanced Breast Cancers - Stock Titan
Rigel Pharmaceuticals, Inc. (RIGL) Latest Stock News & Headlines - finance.yahoo.com
Rigel (RIGL) Q2 2026 Earnings Call Transcript - The Globe and Mail
Rigel Pharmaceuticals (RIGL) Short Interest & Short Float | Updated Aug 2026 $RIGL - MarketBeat
Rigel Pharmaceuticals, Inc. $RIGL Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Rigel Pharmaceuticals (RIGL) Advances 3.71% to $41.66 as Bullish Momentum Targets $43.74 ResistanceBollinger Band - dars.gov.et
Janus Henderson Group PLC Boosts Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals Inc (RIGL) Stock News Today - TradingKey
Rigel Pharmaceuticals Inc (RIGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Issues Pessimistic Estimate for RIGL Earnings - MarketBeat
Pacer Advisors Inc. Purchases 48,882 Shares of Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Cantor Fitzgerald Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $43 - 富途牛牛
HC Wainwright Issues Pessimistic Forecast for RIGL Earnings - MarketBeat
Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts - simplywall.st
Rigel Pharmaceuticals in-licenses Veppanu, targ... - Pluang
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):